Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 04, 2019 08:00 ET | Source: Jounce Therapeutics, Inc.

Jounce Therapeutics to Present at Cowen and Company 39th Annual Health Care Conference

CAMBRIDGE, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
February 28, 2019 08:00 ET | Source: Jounce Therapeutics, Inc.

Jounce Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Wednesday, March 6, 2019

CAMBRIDGE, Mass., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
February 27, 2019 16:35 ET | Source: Jounce Therapeutics, Inc.

Jounce Therapeutics to Present Data from its JTX-2011 and JTX-8064 Programs at the 2019 American Association for Cancer Research (AACR) Annual Meeting

ICONIC Clinical Data Demonstrates Improved PFS/OS in Patients with Emergence of JTX-2011 Mechanistic Biomarker (ICOS high CD4 T cells) Company to Host Investor Event and Live Webcast on Tuesday,...
January 03, 2019 08:00 ET | Source: Jounce Therapeutics, Inc.

Jounce Therapeutics Completed Enrollment in First Cohort of Phase 1 Clinical Trial with its PD-1 Inhibitor, JTX-4014

CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
January 02, 2019 08:00 ET | Source: Jounce Therapeutics, Inc.

Jounce Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
November 13, 2018 06:30 ET | Source: Jounce Therapeutics, Inc.

Jounce Therapeutics Reports Third Quarter 2018 Financial Results

- Dose escalation cohorts of JTX-2011 Phase 1/2 ICONIC trial, in combination with ipilimumab and in combination with pembrolizumab, on track - - IND filed and clearance to proceed received for...
November 10, 2018 12:20 ET | Source: Jounce Therapeutics, Inc.

Jounce Therapeutics Presents Reverse Translational, Biomarker and Preclinical Data from ICOS Program at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting

- Characterization of emerging ICOS hi CD4 T cells from responding patients provides rationale for JTX-2011 combination therapies - CAMBRIDGE, Mass., Nov. 10, 2018 (GLOBE NEWSWIRE) -- Jounce...
November 06, 2018 08:00 ET | Source: Jounce Therapeutics, Inc.

Jounce Therapeutics to Announce Third Quarter 2018 Financial Results and Host Conference Call on Tuesday, November 13, 2018

CAMBRIDGE, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
November 02, 2018 13:48 ET | Source: Jounce Therapeutics, Inc.

Jounce Therapeutics to Present Two Posters from the JTX-2011 Program at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting

CAMBRIDGE, Mass., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
October 01, 2018 11:39 ET | Source: Jounce Therapeutics, Inc.

Jounce Therapeutics Founder Dr. James P. Allison Jointly Awarded 2018 Nobel Prize in Physiology or Medicine for the Discovery of Cancer Therapy by Inhibition of Negative Immune Regulation

CAMBRIDGE, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...